We have performed an entire-population-based survey of the epidemiology and penetrance of Leber hereditary optic neuropathy (LHON) in Finland -a country that is among the best-studied genetic isolates in the world. During our long-term clinical follow-up period since 1970, we have so far identified 36 LHON families in Finland, comprised of almost 1000 family members. Counting the unaffected family members has been possible thanks to accessible genealogical records, and this has improved the accuracy of our penetrance figures by minimizing the sample bias. Our results, although confirming some well-known features of LHON, indicate that the overall penetrance of LHON is lower than previously estimated, and that affected females have a higher incidence of affected offspring compared to the unaffected females. The prevalence of LHON in Finland is 1:50 000, and one in 9000 Finns is a carrier of one of the three LHON primary mutations.
Introduction
Leber hereditary optic neuropathy (LHON; OMIM 1 # 5 35 000) is a maternally inherited eye disease that generally affects young adults with bilateral central vision loss leading to optic atrophy. 2 The vast majority of LHON cases are associated with one of the three primary mutations in the mitochondrial DNA (mtDNA): MT-ND4/ G11778A, 3 MT-ND1/G3460A 4, 5 or MT-ND6/T14484C. 6 Prominent features in LHON pedigrees are incomplete penetrance and male bias among the affected individuals, reflecting the complex etiology of the disorder. Primary mutations are not sufficient in and of themselves to cause optic atrophy, but the additional factors -mutations in some nuclear gene(s) and/or epigenetic factors -that modify the risk of visual loss are still unknown.
We have performed an extensive epidemiological and penetrance study of LHON aiming to cover the entire population of Finland. We have combined thorough clinical expertise and a long-term follow-up of the Finnish LHON families over the period 1970 -2004 . As a country, Finland is well known for its particular suitability for this kind of study: it has a well-established population history and easily accessible and reliable genealogical records. Owing to a state-sponsored health-care system, medical records are also of high quality, and, in general, the patients and families have a favourable attitude towards health-care professionals and genetic research.
In this article, we describe the outcome of our epidemiological and penetrance study on the population of Finland.
Subjects and methods

Subjects
The clinical follow-up of the Finnish LHON families has been carried out by Turku University Central Hospital since 1970, conducted by one of the authors (E.N.). In our previous studies, 7, 8 new LHON families have been diagnosed and the number of Finnish LHON families has increased to 36 . This in all probability represents if not all, at least the overwhelming majority of the Finnish LHON families. Since the diagnosis of our first LHON patient in 1970 (by E.N.), Turku has been the leading clinical and molecular research centre for LHON in Finland. Ever since, we have maintained close contact networks between practising clinicians and researchers -an interaction that has guaranteed that even families with only a putative LHON diagnosis have been brought to our attention for further clinical and molecular genetic analyses.
We have also updated our previously identified pedigrees. By contacting the families and/or performing genealogical studies using Finnish parish records and civil registers, we have been able to add new individuals to them. In addition, the present clinical status of the family members has been ascertained. After this, we feel confident in concluding that any Finnish LHON cases that still may exist and our group is not aware of, are very few in number and most likely represent single cases, small families or distant branches of the previously diagnosed families.
The total number of subjects in the present study is 932 individuals (472 males and 460 females) after exclusion of all unaffected family members o5 years of age (ages were determined on 31 December 2004) or who had died still unaffected before reaching 5 years. In our series, 5 years is the earliest age at the time of diagnosis of LHON and, therefore, individuals younger than this were excluded. The oldest generations without reliable clinical diagnoses were also excluded.
The category of the affected is composed of cases with acute or subacute optic neuropathy with fundus and visual field findings suggestive of LHON as described previously.
9,10 Maternal relatives not assessed but reported as being unaffected were classified as unaffected. In LHON, affected individuals are usually aware of their ophthalmologic problems. Of the 932 individuals, 140 (108 males and 32 females) were affected with LHON, and of them, 108 (85 males and 23 females) were alive at the end of year 2004. The unaffected individuals were divided into two age cohorts: one containing 792 individuals Z5 years of age and the other containing 649 individuals Z25 years of age. The other age limit, 25 years, can be considered as the average age of onset in LHON. This is based on the literature, as many authors for example, 10, 11 have placed the mean age at onset between the ages of 22.0 years 12 and 27.6 years. 13 
Mutation detection
After informed consent, venous blood samples for molecular genetic analyses were collected from the subjects during their regular follow-up visits to the clinic. The ethical committee of the Hospital District of VarsinaisSuomi approved the study. DNA was extracted from the blood with the standard methods (Nucleon BACC3 kit for blood and cell cultures, Amersham Biosciences, Little Chalfont, UK). The three primary mutations were tested by a standard restriction-fragment length polymorphism (RFLP) analysis of polymerase chain reaction (PCR) fragments. In homoplasmic pedigrees, maternal family members have been proven to carry the same mutation and therefore, not everyone needs to be tested. 14 Thus, maternal relatives of an individual carrying a homoplasmic pathogenic mutation were concluded to be carriers of the same mutation. In the families in which the pathogenic mutation was unknown, the same rationale was used.
MtDNA sequencing
Complete mtDNA sequences were obtained from 35 probands; one proband was excluded because there was not enough DNA to perform the sequencing and no other family members were available. Each fragment was amplified in a standard 25-ml reaction. PCR products were purified for sequencing with the GFXt PCR DNA and Gel Band Purification Kit according to the manufacturer's instructions (Amersham Biosciences, Little Chalfont, UK). The purified PCR products were sequenced. Sequence variants were searched by Sequencher v. 3.0 software (Gene Codes Corporation, Ann Arbor, MI, USA). Mitochondrial haplogroups were determined by RFLP as indicated, 15, 16 and by hypervariable segments (HVS) I and II of the mtDNA (nt 16024 -16383 and 57 -372, respectively) sequencing.
Quantification of heteroplasmy
Heteroplasmy was determined by solid-phase minisequencing as described elsewhere. 8 Individuals harbouring 1 -99% of normal mtDNA were considered heteroplasmic and were included in the study. Individuals with o1% of mutant mtDNA were excluded. Where heteroplasmic individuals had family members with a homoplasmic mutation, these members were included with the heteroplasmic families.
Penetrance and prevalence analysis
We determined penetrance as the proportion of affected individuals from all maternally related family members. All pedigrees were evaluated separately. Additionally, combined penetrance values were calculated for the joint family material, for different primary mutations, for heteroplasmic families, for the two different age cohorts (Z5 and Z25 years of age), and for males and females separately. Penetrances were also determined for males and females in each separate generation where there were Z2 individuals of that particular gender. In addition, females with children were identified (unaffected offspring o25 years of age were excluded) and the number of each mother's affected and unaffected children was counted.
The minimum point prevalence values for LHON patients and primary mutation carriers in the Finnish population were calculated using the most recently published data in Finland -our total population was 5 236 611 individuals (49% males, 51% females) on 31 December 2004 (Statistics Finland).
Results
Distribution of primary mutations
The distribution of the primary mutations, homo-and heteroplasmy, and familial and sporadic pedigrees are shown in Table 1 . Of the 36 Finnish LHON families, 24 (67%) harboured a primary mutation, distributed as follows: MT-ND4/G11778A 53% (19/36 families), MT-ND1/G3460A 11% (4/36) and MT-ND6/T14484C 3% (1/ 36). Among the 24 families with a primary mutation, the ND4/G11778A mutation represents 79% (19/24) , the ND1/ G3460A mutation 17% (4/24) and the ND6/T14484C mutation 4% (1/24) of the families. Out of these 24 families, heteroplasmy was detected in five of them (21%). The proportion of mutant mtDNA in individual members of heteroplasmic families varied from 2 to 98% among females and from 23 to 98% among males (A Puomila, unpublished data). 8 In our series, we had 12 families (33%, 12/36) without a primary mutation. Owing to a confident clinical diagnosis of LHON in these families, they were also included in our study. In 11 families from which complete mtDNA sequences were obtained, none of the sequence variants fulfilled the criteria for a primary pathogenic LHON mutation ( Table 2) .
A relatively large number, a total of 15 families, were sporadic (42%, 15/36), for example with only one affected person diagnosed so far.
Only two of our 36 families are likely to be genealogically related to each other through a maternal ancestor, because they share an identical mtDNA control region sequence (Table 2 ). This suggests that the primary LHON mutations have arisen on several occasions in different mitochondrial backgrounds among the Finnish population.
Eight families (22%, 8/36) -six with ND4/G11778A, one with ND6/T14484C and one without a primary mutationbelong to mitochondrial haplogroup J (six to the subcluster J1 and two to J2). This makes the frequency of haplogroup J significantly higher among LHON patients than among the Finnish controls, among whom the frequency has been established as 6.3% (n ¼ 400) 17 (w 2 ¼ 12.0, Pr0.001).
Penetrance of optic atrophy
The penetrance figures for optic atrophy among the Finnish LHON families are shown in Table 3 . In the first age cohort (Z5 years), the figures were as follows: in homoplasmic ND4/G11778A families, 26% for males and 6% for females, and in homoplasmic ND1/G3460A families, 19% for males and 9% for females. In the other age cohort (Z25 years), the penetrance figures were 31% for males and 8% for females in homoplasmic ND4/ G11778A families, and 24% for males and 10% for females in homoplasmic ND1/G3460A families. Between separate families even with the same primary mutation, the penetrance is highly variable, as demonstrated in Figure 1 .
In the large family A, there is only one affected person, whereas in family B, several family members manifest optic atrophy. Family A belongs to haplogroup H that has been proposed to associate with low penetrance when occurring with the ND6/T14484C mutation. 18 Family B represents haplogroup J which, on the other hand, has been linked to high penetrance in LHON. 19, 20 Overall, the highest penetrance of optic atrophy was observed in the six ND4/G11778A-positive families belonging to mitochondrial haplogroup J: 37% of males (36/97) and 11% of females (10/95) at Z5 years of age, and when only the age group of Z25 years was considered, penetrances were even higher, 40% among males (36/90) and 12% among females (10/86).
To study whether the morbidity has changed over successive generations, penetrances were also determined for each generation separately in all informative pedigrees. No uniform trend towards increasing or decreasing penetrance in subsequent generations was observed in any of the families or different cohorts of families. Instead, among males, there were altogether 21 increasing, four stable, and 15 decreasing transitions from one generation to the next and among females, the corresponding figures were 7, 24 and 12. When data from both genders were combined, 28 of the penetrance figure transitions were increasing, 28 were stable and 27 were decreasing.
Male:female ratio
The well-known male preponderance in developing optic atrophy in LHON was evident. However, the ratio of A73G  C150T  A263G  C295T  309insC  315insC  T489C  A750G  A1438G  A2706G  T4216C  A4769G  C5633T  C7028T  C7476T  A8860G  A9016G  A9494G  G10172A  A10398G  A11251G  G11719A  G11778A  A12612G  G13708A  C14766T  G15257A  A15326G  C15452A  A15662G  G15812A  C16069T  T16126C  C16193T  C16278T  T16519C   2/V  T72C  A93G  A263G  309insC  315insC  A750G  A1438G  A2706G  G3460A  C3549T  G4580A  A4769G  C7028T  G7444A  A8860G  T11899C  A15326G  G15928A  G16153A  T16298C   3/H1  A73G  A263G  309insC  315insC  A750G  A1438G  G3010A  G3460A  A4769G  A8537G  A8860G  A15326G  A16162G  T16519C   4/J1c  A73G  T146C  G185A  G228A  A263G  C295T  315insC  C462T  T489C  A750G  A1438G  A2706G  G3010A  T4216C  A4769G  C6464A  C6554T  C7028T  A8860G  A10398G  A11251G  G11719A  G11778A  G12127A  A12612G  A13681G  G13708A  C14766T  T14798C  A15326G  C15452A  C16069T  C16261T   5/X  A73G  A153G  T195C  G225A  A227G  A263G  315insC  A750G  A1438G  G1719A  A2706G  G4541A  A4769G  T6221C  C6371T  C7028T  T8705C  A8860G  G11719A  G11778A  C12705T  A13966G  T14470C  C14766T  A15326G  A16183C  T16189C  C16192T  C16223T  C16248T  G16255A  C16278T  T16519C   6/H1  A73G  A263G  C295T  309insC  315insC  A750G  A1438G  G3010A  A3447G  A4769G  A8860G  T10108A  A10398G  A10499G  G11778A  G14016A  A15326G  A16162G  T16519C   7/U5a  A73G  C150T  T152C  A263G  309insCC  315insC  515delAC  A750G  A1438G  A2706G  A2757G  T3197C  A4769G  A5656G  C7028T  A7768G  A8860G  G9477A  A10283G  A11467G  G11719A  G11778A  A12308G  G12372A  T12616C  T14182C  C14766T  A15326G  T16093C  T16189C  C16270T  C16465T   8/V  T72C  A263G  309insCCC  315insC  A750G  A1438G  A2706G  G4580A  A4769G  C7028T  A8860G  A13350G  G14016A  A15326G  C15904T  T16298C   9/J1c  A73G  G185A  A263G  C295T  315insC  C462T  T489C  A750G  A1438G  A2706G  G3010A  C4025T  T4216C  A4769G  C7028T  A8860G  A10398G  A11251G  A11413G  G11719A  A12612G  G13708A  C14766T  T14798C  A15326G  C15452A  C16069T  T16311C   11/H1  A93G  A263G  309insCC  315insC  A750G  A1438G  G3010A  A4769G  A8860G  T9101C  A10262G  A16183CC  T16189C  A16194C   12/H1  A263G  315insC  456delC  A750G  A1438G  G3010A  T4452C  A4769G  T7309C  A8860G  A9066G  G11778A  A15326G  T16093C  T16311C   13/J2a  A73G  C150T  T152C  T195C  C295T  310insT  315insC  T319C  T489C  G513A  A750G  A1438G  T1850C  A2706G  A3447G  T4216C  A4769G  C7028T Epidemiology and penetrance of LHON in Finland A Puomila et al C7476T  C7661T  G7789A  A8860G  A10398G  A10499G  C10955A  A11251G  G11377A  G11719A  G11778A  A11797G  A12612G  G13708A  A14133G  C14766T  G15257A  A15326G  C15452A  C16069T  T16126C  G16145A  T16231C  C16261T  C16344T   14/H1  T146C  A263G  309insC  A750G  A1438G  G2098A  G3010A  G3460A  A4769G  A8860G  A15326G  T16519C   15/H3  A263G  309insC  315insC  A750G  A1438G  A4769G  A5423G  T6776C  A8860G  G12795A  T12811C  C13967T  C14766T  A15178G  A15326G  T16311C  T16519C   16/W  A73G  A189G  T195C  T204C  G207A  A263G  315insC  G709A  A750G  T1243C  A1438G  A2706G  A3505G  A4769G  G5046A  G5460A  C7028T  C7864T  G8251A  A8659G  A8860G  A8887G  G8994A  C11674T  G11719A  G11778A  A11947G  T12414C  C12705T  C14766T  A15326G  G15884C  C16223T  C16292T  C16295T  T16519C   17/U5a  A73G  C150T  A263G  309insC  315insC  A750G  A1438G  C1721T  T1834C  A2706G  T3197C  A4732G  A4769G  C5452T  C7028T  A7768G  T8705C  A8860G  G9477A  A11467G  G11719A  A12308G  G12372A  T13617C  A13637G  T14182C  C14766T  A15326G  T15511C  A15924G   18/H3  A263G  309insC  315insC  A750G  A955C  T961C  A1438G  A4769G  T6776C  C7341G  A7606G  A8860G  G11778A  A15326G  G16129A  T16519C   19/U5  A73G  C150T  T217C  A263G  309insCC  315insC  568insC  A750G  A1438G  A2706G  T3197C  A3434G  A4769G  A5656G  C7028T  A7768G  A8860G  G9477A  A11467G  G11719A  G11778A  A12308G  G12372A  G12618A  T13617C  T14182C  C14766T  A15326G  T16189C  C16192T  C16270T   20/J1c  A73G  T146C  G185A  G228A  A263G  C295T  315insC  C462T  T489C  A750G  A1438G  A2706G  G3010A  T4216C  A4769G  C6464A  C6554T  C7028T  A8860G  A10398G  A11251G  G11719A  G11778A  A12612G  A13681G  G13708A  C14766T  T14798C  A15326G  C15452A  C16069T  C16261T   21/V  T72C  A263G  309insC  315insC  A750G  A1438G  A2706G  G4580A  A4769G  C7028T  A8860G  A13350G  G14016A  A15326G  C15904T  T16298C   22/H1  T146C  T152C  A263G  309insCC  315insC  A750G  A1438G  G2098A  G3010A  A4769G  T8286C  A8860G  G11914A  A15326G  G16477A  T16519C   23/H1  G228A  A263G  309insCC  315insC  A750G  A1438G  G3010A  A4769G  T4859C  8290insCCCCCTCTA  A8860G  A12366G  A15326G  T16209C  T16519C   24/U  A73G  A263G  T282C  309insC  315insC  A750G  A1438G  A1811G  A2706G  C3738T  A4769G  A5240G  T6392C  C6455T  C7028T  A7055G  A7299G  A8860G  A9338G  C9365T  T9698C  G9777A  C10733T  A11467G  G11719A  C12135A  A12308G  G12372A  G13145A  C14766T  A15326G  A16146G  T16342C   25/T1  T152C  T195C  A263G  315insC  G709A  A750G  A1438G  G1888A  A2706G  T4216C  A4769G C7028T  G8697A  A8860G  A9338G  C9365T  T10463C  C10733T  A11251G  G11719A  C12633A  G13368A  C14281T  C14766T  G14905A  A15326G  A15607G  G15928A  T16126C  A16163G  T16189C  C16294T  T16519C   26/H3  A263G  309insCC  315insC  A750G  T961C  A1438G  A4769G  T6776C  A8860G  G11778A  A15326G  G16129A  T16519C   27/T2  A73G  T146C  T152C  A263G  315insC  G709A  A750G  G930A  A1438G  G1888A  A2706G  T4216C  A4769G  A4917G  G5147A  C7028T  G8697A  A8860G  A9180G  G9966A  T10463C  A11251G  G11719A  G11778A  A11812G  G13368A  T13768C  A14233G  C14766T  G14905A  A15326G  C15452A  A15607G  G15928A  C16294T  C16296T  T16304C  T16519C   28/T2  A73G  T146C  T152C  A215C  A263G  315insC  G709A  A750G  G930A  A1438G  G1888A  A2706G  T4216C  A4769G  A4917G  G5147A  C7028T  G8697A  A8860G  A9180G  G9966A  T10463C  A11251G  G11719A  G11778A  A11812G  G13368A  A13618G  A14233G  A14608G  A14617T  C14766T  G14905A  A15326G  C15452A  A15607G  G15928A  T16126C  16257delC  C16294T  C16296T  T16304C  T16519C   29/H  A263G  309insCC  315insC  G709A  A750G  A1438G  C2259T  A4745G  A4769G  G7337A  A8842G  A8860G  T10101C  G11778A  T13326C  C13680T  C14872T  A15326G  C16261T  T16311C   30/H3  A73G  C150T  T217C  A263G  309insC  315insC  568insC  A750G  A1438G  G3460A  A4769G  A5423G  T6776C  A8860G  G9477A  A11467G  G11719A  G12372A  G12618A  G12795A  T12811C  T13617C  C13967T  A15326G  T16189C  C16192T  C16270T   31/H2  T152C  A263G  309insC  315insC  G951A  A8860G  G11778A  A15326G  C16354T   32/H  A263G  309insCC  315insC  A750G  A1438G  A4769G  G6480A  A8860G  G9055A  T14470A  A15326G  C16111T  C16221T  T16519C   33/J1c  A73G  G185A  A263G  C295T  309insC  C462T  T489C  A750G  A1438G  A2706G  G3010A  T4216C  A4769G  C7028T  A8860G  A8923G  T10101C  A10398G  A11251G  G11719A  G11778A  A12612G  C12891T  G13708A  C14766T  T14798C  A15326G  C15452A  C16069T  T16126C  T16519C   34/J1c  A73G  T146C  G185A  G228A  A263G  C295T  315insC  C462T  T489C  A750G  A1438G  A2706G  G3010A  T4216C  A4769G  C6464A  C6554T  C7028T  A8860G  A10398G  A11251G  G11719A  G11778A  G12127A  A12612G  A13681G  G13708A  C14766T  T14798C  A15326G  C15452A  C16069T  C16261T   35/U5  A73G  A263G  315insC  A750G  T1187C  A1438G  A2706G  T3197C  A4769G  C7028T  A8860G  G9055A  G9477A  A9667G  A11467G  G11719A  G11778A  A12308G  G12372A  G13194A  T13617C  C14766T  A14793G  A15218G  A15326G  C16192T  C16256T  C16270T C16291T A16399G
Epidemiology and penetrance of LHON in Finland A Puomila et al affected males vs females was different depending on the mutation in question. Among homoplasmic ND4/ G11778A-positive patients, the male:female ratio was 4.4:1 (80:18 individuals). The homoplasmic ND1/G3460A mutation was associated with a less prominent gender bias: the male:female ratio was 2.0:1 (10:5). In the ND6/ T14484C family, there was only one affected male. Among individuals without a primary mutation, the ratio was 1.9:1 (17:9). The overall male:female ratio among all LHON patients was 3.4:1 (108:32).
Affected and unaffected females' risk of having affected offspring
To address whether the risk of affected offspring is greater among affected than unaffected females, we studied all mother -child pairs. We identified altogether 230 females who had offspring (unaffected offspring o25 years of age were excluded) ( Table 4) . Of the 230 mothers, 23 were affected and had a total of 52 descendants, that is on average 2.26 children each. The 207 unaffected mothers had 596 descendants (on average 2.88 each). Thus, unaffected mothers had slightly more children than affected mothers. Of the offspring of affected mothers, 38 (73%) were unaffected and 14 (27%) affected, whereas out of the offspring of unaffected mothers, 488 (82%) were unaffected and 108 (18%) affected. In the largest separate cohort, the homoplasmic ND4/G11778A-positive females, the affected mothers' ratio between unaffected and affected offspring was 28:10 (74 -26%) whereas for the unaffected females the ratio was 312:75 (81 -19%). Group comparisons of the affected and unaffected children of the affected and unaffected mothers (carrying A73G  A263G  C295T  309insC  315insC  C462T  T482C  T489C  514delC  515delA  A750G  A1438G  A2706G  G3010A  T3394C  T4216C  A4769G  C7028T  A7184G  A8860G  G10203A  A10398G  A11251G  G11719A  A12612G  G13708A  T13953C  T14484C  C14766T  T14798C  A15326G  C15452A  C15725T  C16069T  T16126C LHON, Leber hereditary optic neuropathy. 
Discussion
When studying epidemiology, large and well-studied research populations are rare but extremely valuable. We have performed an entire-population-based survey on the epidemiology of LHON in Finland, a country that is among the best-studied genetic isolates in the world. We lack some inherited diseases such as cystic fibrosis or phenylketonuria that are common elsewhere, and have our own Finnish disease heritage that is due to our unique population history. However, none of these features are reflected in the molecular genetic parameters of LHON. The frequencies of the LHON primary mutations in Finland do not strikingly differ from most of the other populations studied. In an extensive analysis of 159 LHON families from Northern Europe, the United Kingdom and Australia, 69% of the families carried the ND4/G11778A mutation, 13% the ND1/G3460A mutation and 14% the ND6/T14484C mutation 21 compared with frequencies of 53, 11 and 3%, respectively, in our series. In Denmark, the ND6/T14484C mutation is as infrequent as in Finland (one family out of 30, whereas this frequency was one family out of 36 in our series).
22
Prevalence According to Chinnery et al, 23 LHON is the most common mtDNA disorder. To date, data on the absolute prevalence of LHON in different populations are still sparse. In our 5.2-million population, LHON affects one in 48 487 individuals (2.06/1 00 000) and one in 9351 (10.69/ 1 00 000) carry a primary LHON mutation. Interestingly, this prevalence figure for LHON phenotype is remarkably close to the prevalence estimate of 1:50 000 based on clinical studies before the molecular genetic background of LHON was known. 24 In a recent study of a population in North East England of 2.2 million, 12 prevalence of visual failure due to LHON was one in 31 054 and of primary mutation carriers one in 8500. When the Finnish minimum point prevalence figures were compared with this data, 12 the distribution of the primary mutation prevalence was not statistically significant (w 2 ¼ 1.8, P ¼ 0.20). The minimum point prevalence of LHON phenotype, however, reached slight statistical significance between these two populations (w 2 ¼ 8.6, P ¼ 0.044). In part, it could possibly indicate differences in, for example, the nuclear background between Finnish and English populations. The susceptibility alleles could be more common among the Englishmen. On the other hand, this difference may be due to restricting the English cohort to those at 'working age', that is r65 years of age. In Finland, individuals 465 years of age represent B16% of the population and therefore we included them in our survey. A remarkably lower penetrance for LHON (1:1 13 300) has been observed in Australia (a population of 17 million in 1994), but the prevalence for LHON primary mutations is of similar magnitude, one in 8500. 14 All in all, at least in three 
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Penetrance
In an adult-onset disorder, penetrance values may be highly variable depending on the age limits used in the studies. This is clearly demonstrated in our study, where two different age cohorts result in different penetrance figures. However, we consider excluding young unaffected individuals (o25 years of age) to be reasonable because it can be assumed that a number of them will be affected when reaching the age of 25. The most comparable penetrance values are therefore obtained within one study that is based on a sufficient quantity of research material. In our series, there were substantial penetrance differences even among families carrying the same mutation. This has been observed in other populations as well.
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Penetrance in specific cohorts In our study, the penetrance of optic atrophy was lower than in earlier studies. Among all our families, the penetrance was 27% in males and 8% in females, whereas the majority of earlier reports have given penetrances as high as B50 -60% in males and B10 -20% in females. 22,28 -31 . Our previous estimation was 45% for males and 18% for females. 32 The present lower penetrances are probably due to the fact that in this study, we have done our best to trace all maternal members of the families, which has increased the number of unaffected relatives included. The lowest overall penetrances have been reported in a genealogical study by Mackey: 20% for males and 4% for females.
14 When the penetrance values were calculated for each generation in all informative pedigrees, we found no evidence that the risk of developing LHON systematically changes over successive generations. In our series of 83 transitions from a previous generation to the subsequent in 25 informative pedigrees, the penetrance figures fluctuated seemingly randomly. No evident consistent changes towards either an increasing or decreasing risk of optic atrophy were seen in all the pedigrees combined or in any given cohort. This is in opposition to the results of Mackey 14 too, has reported two male sib-pairs, neither carrying any of the primary mutations. In 11 of our families, none of the mtDNA sequence variants fulfilled the criteria for a primary pathogenic mtDNA mutation (Table 2) . One intriguing and also diagnostically challenging possibility that remains is that there is some bilateral optic atrophy; clinically very similar to LHON but not associated with mtDNA defects. Thus the underlying genetic defect may be nuclear and inheritance simply mimics maternal inheritance.
Sporadic cases and heteroplasmic families Despite LHON being an inherited disease, many diagnosed individuals represent isolated cases even in large families. The proportion of sporadic cases has been reported to be 57% for the ND4/G11778A, 22% for the ND1/G3460A and 35% for the ND6/T14484C mutation. 13, 35 In our series, the proportion of sporadic families is 15 out of 36 families (42%). The large degree of sporadicity, however, is not exceptional and restricted solely to Finns. In two previous studies, similar results were obtained: 36% 30 and 40% 31 , although this is in contrast with 2% in Australia.
14 Sporadic cases are often heteroplasmic, and correspondingly, four out of our five heteroplasmic families are sporadic. Heteroplasmy has been proposed to be a penetrance-decreasing factor, 36 although individuals with a relatively low proportion of mutant mtDNA in their blood can still become affected and females with extremely low proportion of mutant mtDNA can have affected offspring. 37 In the present survey, the heteroplasmic families were too small to provide any comparable penetrance figures.
Haplogroup J families Out of the Finnish LHON families, eight (22%; six ND4/G11778A-positive, one ND6/ T14484C-positive and one without a primary mutation) belong to mitochondrial haplogroup J, making haplogroup J significantly more frequent among our LHON families than among the Finnish controls (6.3% in Niemi et al 17 ).
This, and especially the high frequency of ND4/G11778A-and ND6/T14484C-positive families in haplogroup J, has been seen in previous studies as well. 7, 19, 20, 38 In our series, the highest penetrance was seen in the ND4/G11778A mutation which occurred in the haplogroup J background, in accordance with previous studies. 19, 20 Recently, several studies on neurological diseases have supported the view that mtDNA variation in certain haplogroups may not be completely neutral but may either increase or decrease the risk of developing the symptoms. 39 , 40 Reynier et al 41 , for example, suggest that haplogroup J could be a genetic factor for visual impairment. Despite these haplogroup J-associated findings in LHON, the observed phenomenon is difficult to explain in the light of the present limited knowledge of the role which mtDNA variation ultimately plays. The hypothesis is that certain mtDNA polymorphisms are, by themselves, neutral but in specific combinations together with pathogenic mtDNA mutations they might be deleterious and increase the risk of disease expression or produce a more severe clinical phenotype. 42 
Male preponderance
The well-established concept of male preponderance in LHON was also seen in this study. The male:female ratios of the affected family members are listed in Table 5 . The Finnish ratios are in accordance with those obtained earlier from other Caucasoid populations. For example, our ratios were compared with the English material 12 and the distributions were not statistically significantly different for any of the groups -ND4/G11778A-positive, ND1/ G3460A-positive, all primary mutations combined or the whole material combined (data not shown). When the primary mutations are compared, the male preponderance is the most prominent in patients with the ND6/T14484C mutation and less obvious in patients with the ND1/G3460A mutation (Table 5 ). This may be related to the differences in the biochemical consequences of the primary mutations. In an extensive respiration and enzymological analysis on lymphoblast and cybrid mitochondria isolated from 19 LHON patients, 46 the most severe biochemical defect was detected for the ND1/ G3460A mutation, an intermediate one for the ND4/G11778A mutation, and the mildest for the ND6/ T14484C mutation. Female carriers of the biochemically most severe ND1/G3460A mutation seem to become affected almost as often as males, whereas among carriers of other, less severe mutations, a greater proportion of females remains unaffected. Man et al 38 have proposed that the ND1/G3460A is a 'stronger' mutation and less susceptible to the epistatic and epigenetic factors influencing the expression of the ND4/G11778A and ND6/ T14484C mutations.
Affected and unaffected females' risk of having affected offspring In our family material, there were 230 females with offspring (unaffected offspring o25years of age were excluded). The unaffected mothers had slightly more descendants than the affected mothers. The affected females had a higher incidence of affected offspring than the unaffected females (P ¼ 0.034). This is in accordance with the study of Harding et al 30 in which 58 females were analysed and affected mothers had statistically significantly more affected offspring than did unaffected mothers.
Conclusions
Our survey was performed to obtain a clear and defined picture of the epidemiology, prevalence and penetrance of LHON in a well-studied population of an entire country. Adult-onset mitochondrial disorders, such as LHON, are a problematic field in epidemiology, but in a well-known and accessible study population, variability due to sampling effects can be avoided and accuracy is therefore improved. Complete understanding of these diseases can be achieved only when the interplay between our two genomes, nuclear and mitochondrial, in each disorder has been clarified. 
